Biomarin Pharmaceutical Inc (MIL:1BMRN)
€ 70.52 0 (0%) Market Cap: 13.31 Bil Enterprise Value: 13.36 Bil PE Ratio: 70.93 PB Ratio: 2.84 GF Score: 62/100

Biomarin Pharmaceutical Inc at Cowen Health Care Conference (Virtual) Transcript

Mar 07, 2022 / 05:50PM GMT
Philip M. Nadeau
Cowen and Company, LLC, Research Division - MD & Senior Research Analyst

Good afternoon, and welcome once again to Cowen and Company's 42nd Annual Healthcare Conference. I'm Phil Nadeau, one of the biotech analyst here at Cowen. And it's my pleasure to moderate a fireside chat with J.J. Bienaime, Chairman and CEO of BioMarin. J.J., I'll hand it to you to begin with some opening remarks.

Jean;Jacques Bienaime
BioMarin Pharmaceutical Inc. - Chairman & CEO

Thank you. Thank you, Phil, for joining us and all of you for joining us today. I would say the financial, commercial and regulatory momentum at BioMarin has never been stronger as we described on our last quarter call with the addition of what is likely to be our largest market opportunity to date, VOXZOGO, for the treatment of achondroplasia. We expect to transition to sustainable GAAP profitability this year.

I would say the combination of VOXZOGO, and our foundational base business is expected to drive double-digit growth this year and beyond. And despite

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot